Overview

Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung

Status:
Completed

Trial end date:
2010-12-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as irinotecan, leucovorin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving cetuximab together with combination chemotherapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving cetuximab together with combination chemotherapy works as first-line therapy in treating patients with colorectal cancer that has spread to the liver and/or lung.

Phase:

Phase 2

Details

Lead Sponsor:

National Cancer Institute, France

Collaborator:

University Hospital, Grenoble

Treatments:

Calcium
Cetuximab
Fluorouracil
Irinotecan
Leucovorin
Levoleucovorin